High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer: Treatment Evolution and Mature Results

Zamboglou, Nikolaos; Tselis, Nikolaos; Baltas, Dimos; Buhleier, Thomas; Martin, Thomas J.; Milickovic, N.; Papaioannou, S.; Ackermann, Hanns; Tunn, U.

doi:10.1016/j.ijrobp.2012.07.004

Cited by 143 publications

(88 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Focal therapy may be least likely to improve rectal toxicity, given the already low reported rates associated with HDR prostate monotherapy. The largest reported series of HDR monotherapy observed a 1.6% rate of late grade 3 þ rectal toxicity (21). Patient-reported outcomes demonstrate higher rates of rectal toxicity and impact on quality of life and the reductions in dose of O30% seen with 1/3 and 1/6G targets in this study may result in real improvements in patientreported outcomes.…”

Section: Rectal Toxicitymentioning

confidence: 53%

From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis

et al. 2015

View full text Add to dashboard Cite

PURPOSE: To assess the magnitude of dosimetric reductions of a focal and ultra-focal high-doserate (HDR) prostate brachytherapy treatment strategy relative to standard whole gland (WG) treatment. METHODS AND MATERIALS: HDR brachytherapy plans for five patients treated with WG HDR monotherapy were optimized to assess different treatment strategies. Plans were generated to treat the hemigland (HG), one-third gland (1/3G), and one-sixth gland (1/6G), as well as to assess treating the WG with a boost to one of those sub-volumes (WG þ HG, WG þ 1/3G, WG þ 1/6G). Dosimetric parameters analyzed included Target D90%, V100%, V150%, Bladder (B), Rectal (R), Urethral (U) D0.1, 1 and 2cc, Urethral V75%, and the V50% to the contralateral HG. Two-tailed t tests were used for comparison of means, and p-values less than 0.05 were considered statistically significant. RESULTS: Target objectives (D90 O 100% and V100 O 97%) were met in all cases. Significant organs at risk dose reductions were achieved for all approaches compared with WG plans. 1/6G vs WG plans resulted in the greatest reduction in dose with a mean bladder D2cc 24.7 vs 64.8%, rectal D2cc 32.8 vs 65.3%, urethral D1cc 52.1 vs 103.8%, and V75 14.5 vs 75% ( p ! 0.05 for all comparisons). CONCLUSION: Significant dose reductions to organs at risk can be achieved using HDR focal brachytherapy. The magnitude of the reductions achievable with treating progressively smaller sub-volumes suggests the potential to reduce morbidity, but the clinical impact on morbidity and tumor control remain to be investigated. Ó

show abstract

Section: Rectal Toxicitymentioning

confidence: 53%

From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, the present biochemical outcome data remains relatively early. However, the data are important (17) showed that the 3, 5 and 8 year biochemical control rates were 97, 94 and 90%, with no significant differences between the risk groups. In our cohort, 91.6% of patients overall were free of biochemical relapse at 3 years.…”

Section: Discussionmentioning

confidence: 91%

“…Therefore, it is unlikely that the rate of urethral strictures will significantly change with longer follow-up (Tables II and III). Zamboglou et al (17) recently reported a large series in which 718 patients were treated with HDR monotherapy. This previous study showed that late Grade 3 GU toxicity was 3.5%, which compared favorably with 3.1% in the present series.…”

Section: Discussionmentioning

confidence: 99%

Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer

Ashida

Yamasaki

Takagi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the feasibility and preliminary outcomes of high-dose-rate (HDR)-brachytherapy as a monotherapy in two fractions within 1 day for localized prostate cancer, including high-/very high-risk cases. Among the 68 patients treated with HDR monotherapy between July 2011 and December 2014, 65 had a minimal follow-up of 12 months without adjuvant androgen deprivation therapy and were enrolled in the present study [42/65 (64.6%) exhibited high-/very high-risk diseases]. HDR monotherapy was performed in two fractions with a minimal interval of 6 h and the prescribed dose was 13.5 Gy (x2). Adverse events (AEs) were assessed using Common Terminology Criteria for Adverse Events (version 4;

show abstract

“…В настоящее время имеется порядка 10 достаточно крупных иссле-дований, посвященных оценке результатов лечения больных с помощью ВДБТ в режиме монотерапии. Средний срок наблюдения за пациентами составляет от 2,7 до 8 лет [35][36][37][38][39][40][41]. Наиболее длительные сроки на-блюдения (около 8 лет) провели калифорнийские ис-следователи D. J. Demanes и соавт.…”

Section: особенности проведения различных видов бтunclassified

Brachytherapy for prostate cancer: Comparative characteristics of procedures

Kanaev¹,

Новиков²,

Novikov³

et al. 2015

Onkourologiya

View full text Add to dashboard Cite

High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer: Treatment Evolution and Mature Results

Cited by 143 publications

References 24 publications

From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis

From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis

Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer

Brachytherapy for prostate cancer: Comparative characteristics of procedures

Contact Info

Product

Resources

About